$2.12-0.08 (-3.64%)
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States.
Connect Biopharma Holdings Limited in the Healthcare sector is trading at $2.12 with a market capitalization of $140M. Wall Street consensus targets $7.07 (7 analysts), implying a +233.6% move over the next 12 months. The stock is currently 45% below its 52-week high of $3.82, remaining 8.2% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacer...
Connect Biopharma (NASDAQ:CNTB) Chief Executive Officer Barry Quart said the company’s rademikibart program continues to show a differentiated clinical and mechanistic profile as the company awaits mid-2026 data from its SEABREEZE study. Speaking during a fireside chat with H.C. Wainwright analyst
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Connect Biopharma (NASDAQ:CNTB) shared new clinical and preclinical updates on rademikibart, its IL-4 receptor alpha monoclonal antibody, highlighting preliminary top-line results from an intravenous (IV) clinical pharmacology study in asthma and COPD and presenting phase III atopic dermatitis data
Connect Biopharma (NASDAQ:CNTB) CEO Barry Quart outlined the company’s focus on rademikibart, an IL-4 receptor alpha monoclonal antibody he described as a “next-generation DUPIXENT,” during a presentation at the Leerink Partners Global Healthcare Conference. Quart emphasized both chronic and acute-c
Connect Biopharma (NASDAQ:CNTB) CEO Barry Quart told investors at Oppenheimer’s 36th Annual Healthcare Life Science Conference that the company is advancing its lead asset, rademikibart, into what it described as a novel treatment approach for acute exacerbations of asthma and chronic obstructive pu